Literature DB >> 16132298

Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender.

T S Mir1, M Flato2, J Falkenberg3, M Haddad4, R Budden4, J Weil3, S Albers2, S Laer2.   

Abstract

Children with congenital heart disease need adequate diagnostic classification regarding their cardiovascular status (CVS). N-terminal brain natriuretic peptide (N-BNP) plasma concentration indicates dysfunction of the cardiovascular system and guides decisions concerning treatment and prognosis. Reference values are established for adults, with age-dependent increasing values and higher values in women. To avoid misclassification concerning the CVS, a large group of healthy children and adolescents can be used show the relationship between gender, age, and N-BNP and these can serve as reference values. N-BNP was measured in 434 healthy subjects (240 female and 194 male) with ages ranging from 0 to 32 years without any cardiovascular disease or renal or hepatic impairment. Measurements were performed with an electrochemiluminescence immunoassay from Roche Diagnostics. Mean N-BNP decreased from 12.6 fmol/ml (0-9 years; n = 79) to 9.41 fmol/ml (10-14 years; n = 154) and in adolescents from 6.1 (15-19 years; n = 99) to 4.8 fmol/ml (> 19 years; n = 102) in adults (p < 0.05). Mean N-BNP concerning gender did not differ in any age group younger than 19 years. In contrast, the adult female group had 78% higher N-BNP compared to the male group (p < 0.05). There was a significant peak in N-BNP at the age of 12-14 years. This study shows that reference values for N-BNP differed profoundly in children compared to adults and were up to 260% higher in children without any gender difference. Therefore, these reference values will help to avoid CVS misclassification in children for the biomarker N-BNP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16132298     DOI: 10.1007/s00246-005-1022-4

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  23 in total

1.  Cardiac peptides differ in their response to exercise. Implications for patients with heart failure in clinical practice.

Authors:  J A Wijbenga; A H Balk; F Boomsma; A J Man in 't Veld; C Hall
Journal:  Eur Heart J       Date:  1999-10       Impact factor: 29.983

Review 2.  Cardiac hormones: diagnostic and therapeutic potential.

Authors:  J G Lainchbury; E A Espiner; M G Nicholls; A M Richards
Journal:  N Z Med J       Date:  1997-06-27

3.  Estrogen regulation of angiotensin-converting enzyme mRNA.

Authors:  P E Gallagher; P Li; J R Lenhart; M C Chappell; K B Brosnihan
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

Review 4.  BNP and congestive heart failure.

Authors:  Martin R Cowie; Gustavo F Mendez
Journal:  Prog Cardiovasc Dis       Date:  2002 Jan-Feb       Impact factor: 8.194

Review 5.  B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure.

Authors:  A Maisel
Journal:  J Card Fail       Date:  2001-06       Impact factor: 5.712

6.  Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure.

Authors:  Thomas S Mir; Sönke Marohn; Stephanie Läer; Michele Eiselt; Oswin Grollmus; Jochen Weil
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

7.  Plasma brain natriuretic peptide concentration: impact of age and gender.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

8.  B-type natriuretic peptide levels in congenital heart disease.

Authors:  C G Cowley; J D Bradley; R E Shaddy
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

9.  Studies of cardiopulmonary bypass in children: implications for the regulation of brain natriuretic peptide.

Authors:  A Ationu; D R Singer; A Smith; M Elliott; M Burch; N D Carter
Journal:  Cardiovasc Res       Date:  1993-08       Impact factor: 10.787

10.  N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states.

Authors:  Marianne Schultz; Jens Faber; Caroline Kistorp; Anne Jarløv; Frants Pedersen; Niels Wiinberg; Per Hildebrandt
Journal:  Clin Endocrinol (Oxf)       Date:  2004-01       Impact factor: 3.478

View more
  14 in total

1.  Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery.

Authors:  T S Mir; C Haun; C Lilje; S Läer; J Weil
Journal:  Pediatr Cardiol       Date:  2006 Mar-Apr       Impact factor: 1.655

2.  Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

Authors:  Michael G Fradley; Martin G Larson; Susan Cheng; Elizabeth McCabe; Erin Coglianese; Ravi V Shah; Daniel Levy; Ramachandran S Vasan; Thomas J Wang
Journal:  Am J Cardiol       Date:  2011-08-23       Impact factor: 2.778

3.  NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease.

Authors:  Roberto F Machado; Mariana Hildesheim; Laurel Mendelsohn; Alan T Remaley; Gregory J Kato; Mark T Gladwin
Journal:  Br J Haematol       Date:  2011-06-21       Impact factor: 6.998

4.  Relationship of brain natriuretic peptide concentrations to left ventricular function and adverse outcomes in children with end-stage renal disease undergoing hemodialysis.

Authors:  Sana Ouali; Iheb Bougmiza; Saoussen Abroug; Asma Omezzine; Helmi Ben Salem; Elyes Neffeti; Fahmi Remedi; Ali Bouslema; Abdelaziz Harabi; Essia Boughzela
Journal:  Pediatr Cardiol       Date:  2011-02-20       Impact factor: 1.655

5.  Aminoterminal Pro B-Type Natriuretic Peptide (NT-proBNP) Levels for Monitoring Interventions in Paediatric Cardiac Patients with Stenotic Lesions.

Authors:  Eva Welisch; Knut Kleesiek; Nikolaus Haas; Kambiz Norozi; Ralf Rauch; Guido Filler
Journal:  Int J Pediatr       Date:  2010-02-24

6.  Evaluation by N-terminal prohormone of brain natriuretic peptide concentrations and ross scoring of the efficacy of digoxin in the treatment of heart failure secondary to congenital heart disease with left-to-right shunts.

Authors:  Ozlem Elkiran; Ayse Sandikkaya; Gulendam Kocak; Cemsit Karakurt; Cagatay Taskapan; Saim Yologlu
Journal:  Pediatr Cardiol       Date:  2013-03-13       Impact factor: 1.655

7.  Exercise testing in adults after repair of aortic coarctation: evaluation of cardiopulmonary exercise capacity and B-type natriuretic protein levels.

Authors:  Olga Trojnarska; Adrian Gwizdala; Magdalena Lanocha; Agnieszka Katarzynska; Slawomir Katarzynski; Zofia Oko-Sarnowska; Andrzej Szyszka; Ewa Chmara
Journal:  Tex Heart Inst J       Date:  2007

Review 8.  NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.

Authors:  Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

Review 9.  The potential and limitations of plasma BNP measurement in the diagnosis, prognosis, and management of children with heart failure due to congenital cardiac disease: an update.

Authors:  Massimiliano Cantinotti; Yuk Law; Simona Vittorini; Maura Crocetti; Marotta Marco; Bruno Murzi; Aldo Clerico
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

10.  Aminoterminal brain natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive heart failure.

Authors:  Evelyn Lechner; Roland Gitter; Rudolf Mair; Miklos Pinter; Elisabeth Schreier-Lechner; David Vondrys; Gerald Tulzer
Journal:  Pediatr Cardiol       Date:  2008-04-08       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.